167 related articles for article (PubMed ID: 8050207)
21. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative.
Coodley GO; Jorgensen M; Kirschenbaum J; Sparks C; Zeigler L; Albertson BD
Am J Med; 2008 Jul; 121(7):604-10. PubMed ID: 18538295
[TBL] [Abstract][Full Text] [Related]
22. Effect of combining viscous fibre with lovastatin on serum lipids in normal human subjects.
Agrawal AR; Tandon M; Sharma PL
Int J Clin Pract; 2007 Nov; 61(11):1812-8. PubMed ID: 17935545
[TBL] [Abstract][Full Text] [Related]
23. Short-term effects of renal transplantation on plasma lipids and lipoprotein lipase in children with congenital nephrosis.
Antikainen M; Holmberg C; Taskinen MR
Clin Nephrol; 1994 May; 41(5):284-9. PubMed ID: 8050208
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
Frohlich J; Brun LD; Blank D; Campeau L; Crockford P; Curnew G; Dafoe W; Davignon J; Dufour R; Emery G
Can J Cardiol; 1993 Jun; 9(5):405-12. PubMed ID: 8348392
[TBL] [Abstract][Full Text] [Related]
25. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome.
Büyükçelik M; Anarat A; Bayazit AK; Noyan A; Ozel A; Anarat R; Aydingülü H; Dikmen N
Turk J Pediatr; 2002; 44(1):40-4. PubMed ID: 11858378
[TBL] [Abstract][Full Text] [Related]
26. [Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia].
Jover E; Aranda JL; Nogués X; del Palacio A; Rubiés-Prat J
Med Clin (Barc); 1996 May; 106(20):776-9. PubMed ID: 8801396
[TBL] [Abstract][Full Text] [Related]
27. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
28. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Velussi M
Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
[TBL] [Abstract][Full Text] [Related]
29. Continued benefit of lovastatin in the treatment of hypercholesterolemia in 36 patients.
Wallace MB; Warren SG; Bates MC; Robinson PA
W V Med J; 1995 Feb; 91(2):50-3. PubMed ID: 7610642
[TBL] [Abstract][Full Text] [Related]
30. Long-term effects of low molecular weight heparin on lipid parameters in hemodialysis patients.
Elisaf MS; Bairaktari H; Germanos N; Pappas M; Koulouridis E; Papagalanis N; Siamopoulos KC
Int Angiol; 1996 Sep; 15(3):252-6. PubMed ID: 8971586
[TBL] [Abstract][Full Text] [Related]
31. Lipid-lowering effects of lovastatin in CAPD patients.
Jacobs RH; Lal SM; Nolph KD
Adv Perit Dial; 1993; 9():288-90. PubMed ID: 8105945
[TBL] [Abstract][Full Text] [Related]
32. Reduction of hyperlipidemia with 3-sn-polyenyl-phosphatidylcholine in dialysis patients.
Kirsten R; Heintz B; Nelson K; Oremek G
Int J Clin Pharmacol Ther Toxicol; 1989 Mar; 27(3):129-34. PubMed ID: 2722308
[TBL] [Abstract][Full Text] [Related]
33. Dietary cholesterol induced changes in lipid profile in patients with nephrotic syndrome and chronic renal failure.
Jain PK; Arora RC; Agarwal N; Garg RK; Arora S; Gurbaxani RK; Sharma D
J Assoc Physicians India; 1991 Oct; 39(10):751-3. PubMed ID: 1816199
[TBL] [Abstract][Full Text] [Related]
34. [Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins].
Kłosiewicz-Latoszek L; Nowicka G; Szostak WB
Wiad Lek; 1993 Aug; 46(15-16):581-5. PubMed ID: 7975581
[TBL] [Abstract][Full Text] [Related]
35. Effect of lovastatin and bezafibrate on cyclosporine-induced hyperlipidemia in rabbits.
Hidalgo L; López-Miranda J; Espino A; Alcala J; Blanco J; Prada JL; Rodríguez M; Jiménez-Perepérez JA; Jansen S; Pérez-Jiménez F
Transplant Proc; 1995 Apr; 27(2):1857-61. PubMed ID: 7725532
[No Abstract] [Full Text] [Related]
36. Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome.
Tokoo M; Oguchi H; Terashima M; Tokunaga S; Miyasaka M; Hora K; Higuchi M; Yoshie T; Furuta S
Nihon Jinzo Gakkai Shi; 1992 Apr; 34(4):397-403. PubMed ID: 1635284
[TBL] [Abstract][Full Text] [Related]
37. Lipoprotein abnormalities in adult nephrotic syndrome.
Ongajyooth L; Sirisalee K; Laohaphand T; Parichatiganond P; Shayakul C; Nilwarangkur S
J Med Assoc Thai; 1993 Sep; 76(9):512-20. PubMed ID: 7964258
[TBL] [Abstract][Full Text] [Related]
38. [The effect of lovastatin on the development of adriamycin nephropathy in rats].
Tesar V; Zima T; Poledne R; Stejskalová A; Tĕmínová J; Stípek S
Sb Lek; 1995; 96(1):35-42. PubMed ID: 8711364
[TBL] [Abstract][Full Text] [Related]
39. Toxicity of lovastatin in rats with experimentally induced nephrotic syndrome.
Joven J; Vilella E; Camps J; Masana L; Turner PR; Simó JM; Villabona C
Nephron; 1990; 56(4):399-404. PubMed ID: 2079999
[TBL] [Abstract][Full Text] [Related]
40. Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome.
de Zeeuw D; Gansevoort RT; Dullaart RP; de Jong PE
J Hypertens Suppl; 1995 Jul; 13(1):S53-8. PubMed ID: 18800457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
